Aktieanalys

Hansa Biopharma: Imlifidase records a very healthy improvement during Q4 after a quarter with low activity - Redeye

Redeye Publicerad: 08 Jan 09:02

Hansa delivers a positive surprise in Q4 as Idefirix records European product sales of SEK 43m in Q4, which compares with our expected SEK 23m and SEK 16m in Q3. In Q4, Hansa experienced support from countries like the UK, Spain and Germany. The increased early Q4 product sales support is also positive, as Idefirix will secure additional sales related to the Eurotransplant program during 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/969477/hansa-biopharma-preliminary-q4-imlifidase-records-a-very-healthy-improvement-during-q4-after-a-quarter-with-low-activity?utm_source=finwire&utm_medium=RSS

Nyheter om Hansa Biopharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!